NK/NKT cells

Molecular group: 
Immune cells
NK/NKT cells
Plasmodium strain: 
Plasmodium berghei ANKA
pRBC infection titer: 
Mouse genetic background (Con): 
Level of backcrossing: 
Backcrossed for 6 generations
Experimental treatment group (EG): 
NKC complex C57BL/6 (BALB.B6-Cmv1r)
Lethal infection (Con): 
20% (at the end of observation day 17)
Lethal infection (EG): 
50% (at the end of observation day 16)
Pathology (Con): 
CM (20%)
Pathology (EG): 
CM (50%)
Parasitemia (EG vs Con): 
Additional phenotypes (EG vs Con): 
Sequestration of pRBC and macrophages in cerebral vasculature; depletion of NK cells by anti-asialo GM1 treatment did not reverse the increased susceptibility to CM (40 % survival); ↑ % of CD44+Vb8+ and NK1.1+abTCR+ cells in spleen early during infection; adoptive transfer of CD44+Vb8+ NKT cells from BALB/c.B6-Cmv1r mice into BALB/c mice ↑ susceptibility to CM (33.4 %) and adoptive transfer of CD44+Vb8+ NKT cells from BALB/c mice into BALB/c.B6-Cmv1r mice ↓ susceptibility to CM (25 %); naïve CD44+Vb8+ NKT cells produced similar IL-4 and IFN-g when stimulated with anti-CD3 and ↑ IFN-g when stimulated with anti-NK1.1 (in vitro); similar proliferation and IL-4 production and no downregulation of IFN-g production later in infection when infected CD44+Vb8+ NKT cells were stimulated with a-GalCer; similar intracellular IL-4 and ↑ IFN-g production (ex vivo) by CD44+Vb8+ NKT cells; differential expression of NKC markers such as NK1.1 and members of the Ly49 gene superfamily, similar expression of NKG2A/C/E and Ly49C/I
Hansen et al., 2003, Immunity